文献速递肝病

粒细胞集落刺激因子治疗慢加急性肝衰竭:多中心随机试验

Granulocyte-colony stimulating factor (G-CSF) to treat acute-on-chronic liver failure: A multicenter randomized trial (GRAFT study).
PubMed 文献 · J Hepatol · 2021-08-05

这项多中心、前瞻性、对照、开放标签II期研究纳入176例符合EASL-CLIF标准的ACLF患者,随机接受G-CSF(前5天每日5 μg/kg,此后每3天一次至第26天)联合标准药物治疗(SMT)或单用SMT。结果显示,G-CSF组90天无移植生存率为34.1%,SMT组为37.5%(HR 1.05;95%CI 0.711-1.551;p=0.805),两组360天无移植生存和总生存均无差异,G-CSF未改善肝功能评分、感染发生或亚组生存,研究因无效提前终止。

要点

  • G-CSF未改善ACLF患者90天无移植生存率(34.1% vs 37.5%,HR 1.05,p=0.805)。
  • 360天无移植生存和总生存两组无差异(HR 0.998和1.058)。
  • G-CSF不应作为ACLF的标准治疗,临床研究外不推荐使用。

核心结论

  • 与既往研究不同,G-CSF对ACLF患者无显著获益,不应作为标准治疗。

研究设计与样本

  • 多中心、前瞻性、对照、开放标签II期研究,纳入176例符合EASL-CLIF标准的ACLF患者,随机分为G-CSF联合SMT组(n=88)和单用SMT组。

主要发现

  • 90天无移植生存率G-CSF组34.1%,SMT组37.5%(HR 1.05;95%CI 0.711-1.551;p=0.805)。
  • 360天无移植生存(HR 0.998;95%CI 0.697-1.430;p=0.992)和总生存(HR 1.058;95%CI 0.727-1.548;p=0.768)两组无差异。
  • G-CSF未改善肝功能评分、感染发生或无感染、酒精相关ACLF、APASL标准ACLF亚组的生存。
  • 研究因条件效能计算显示无效而提前终止。

临床怎么用

  • G-CSF不应在临床研究之外用于治疗ACLF或肝病。

局限性

  • 研究因无效提前终止。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Based on positive results from small single center studies, granulocyte-colony stimulating factor (G-CSF) is being widely used for the treatment of patients with acute-on-chronic liver failure (ACLF). Herein, we aimed to evaluate the safety and efficacy of G-CSF in patients with ACLF. METHODS: In this multicenter, prospective, controlled, open-label phase II study, 176 patients with ACLF (EASL-CLIF criteria) were randomized to receive G-CSF (5 μg/kg daily for the first 5 days and every third day thereafter until day 26) plus standard medical therapy (SMT) (n = 88) or SMT alone. The primary efficacy endpoint was 90-day transplant-free survival analyzed by Cox regression modeling. The key secondary endpoints were overall and transplant-free survival after 360 days, the development of ACLF-related complications, and the course of liver function scores during the entire observation period. RESULTS: Patients treated with G-CSF had a 90-day transplant-free survival rate of 34.1% compared to 37.5% in the SMT group (hazard ratio [HR] 1.05; 95% CI 0.711-1.551; p = 0.805). Transplant-free and overall survival at 360 days did not differ between the 2 arms (HR 0.998; 95% CI 0.697-1.430; p = 0.992 and HR 1.058; 95% CI 0.727-1.548; p = 0.768, respectively). G-CSF did not improve liver function scores, the occurrence of infections, or survival in subgroups of patients without infections, with alcohol-related ACLF, or with ACLF defined by the APASL criteria. Sixty-one serious adverse events were reported in the G-CSF+SMT group and 57 were reported in the SMT group. In total, 7 drug-related serious adverse reactions occurred in the G-CSF group. The study was prematurely terminated due to futility after conditional power calculation. CONCLUSIONS: In contrast to previous findings, G-CSF had no significant beneficial effect on patients with ACLF in this multicenter controlled trial, which suggests that it should not be used as a standard treatment for ACLF. CLINICALTRIALS. GOV NUMBER: NCT02669680 LAY SUMMARY: Granulocyte-colony stimulating factor was considered as a novel treatment for acute-on-chronic liver failure (ACLF). We performed the first randomized, multicenter, controlled phase II trial, which showed that G-CSF did not improve survival or other clinical endpoints in patients with ACLF. Therefore, G-CSF should not be used to treat liver disease outside clinical studies.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Engelmann C, Herber A, Franke A, et al. Granulocyte-colony stimulating factor (G-CSF) to treat acute-on-chronic liver failure: A multicenter randomized trial (GRAFT study). J Hepatol. 2021. PMID: 34364917. doi:10.1016/j.jhep.2021.07.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。